- The AGIR program, supported by the French Investments for the Future program, aims to accelerate new antibiotics discovery to tackle the global challenge of antibiotic resistance.
- The 2nd milestone of this research program included the screening of a growing number of strains, the validation of the automated tools developed by DEINOVE and the identification of some thirty “hits”.
- The results obtained validate this stage and lead to a payment of €1.5m from Bpifrance.
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio‐based active ingredientsfor cosmetics, announcesthatit has successfully completed the second key milestone ofthe AGIR program ‐ Antibiotics against Resistant Infectious Germs ‐ which is supported by the Investments for the Future Program. This milestone triggered the payment of €1.5m.
“As illustrated by the current coronavirus crisis, infections, whether bacterial or viral, are now rapidly becoming global. It is important to prevent these health emergencies, and to ensure that common infections won’t become lethal again. This risk is increased by the rise in antibiotic resistance. However, only about 40 antibiotics are currently in clinical development, and only 1 out of 4 drugs in the pipeline represent a novel drug class or mechanism of action1. It is becoming urgent to discover new antibacterial treatments,” says Charles Woler, CEO of DEINOVE.
Full PR available here